AR034641A1 - Composicion de liberacion controlada y metodo para producirla - Google Patents
Composicion de liberacion controlada y metodo para producirlaInfo
- Publication number
- AR034641A1 AR034641A1 ARP020102406A ARP020102406A AR034641A1 AR 034641 A1 AR034641 A1 AR 034641A1 AR P020102406 A ARP020102406 A AR P020102406A AR P020102406 A ARP020102406 A AR P020102406A AR 034641 A1 AR034641 A1 AR 034641A1
- Authority
- AR
- Argentina
- Prior art keywords
- salt
- controlled release
- weight
- active substance
- less
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000013270 controlled release Methods 0.000 title abstract 5
- 238000000034 method Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 7
- 239000013543 active substance Substances 0.000 abstract 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 4
- 229920000642 polymer Polymers 0.000 abstract 4
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 abstract 2
- 235000014655 lactic acid Nutrition 0.000 abstract 2
- 239000004310 lactic acid Substances 0.000 abstract 2
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 abstract 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000011259 mixed solution Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pregnancy & Childbirth (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Composición de liberación controlada que contiene una sustancia fisiológicamente activa en un alto contenido, suprime la liberación inicial en exceso, y logra una velocidad de liberación estable durante un largo período. Una composición de liberación controlada que comprende: (1) una sustancia fisiológicamente activa o una sal de la misma en una cantidad de aproximadamente el 14% (p/p) a aproximadamente el 24% (p/p) en base al peso total de la composición, (2) ácido hidroxinaftoico seleccionado del grupo que consiste en ácido 3-hidroxi-2-naftoico y ácido 1-hidroxi-2-naftoico o sal del mismo, y (3) un polímero de ácido láctico o una sal del mismo que tiene un peso molecular medio en peso de 15000 a 50000, en donde el contenido de polímeros que tienen pesos moleculares de 5000 o menos es de aproximadamente el 5% en peso o menos, donde la relación molar de dicho ácido hidroxinaftoico o una sal del mismo respecto de dicha sustancia fisiológicamente activa o una sal de la misma es de 3:4 a 4:3. Un método para producir dicha composición de liberación controlada que comprende la eliminación de un solvente de una solución mixta de una sustancia fisiológicamente activa o sal de la misma, y un polímero de ácido láctico o una sal del mismo que tiene un peso molecular medio en peso de 15000 a 50000, en donde el contenido de los polímeros que tienen pesos moleculares de 5000 o menos es del orden del 5% en peso o menos. Un medicamento que comprende dicha composición de liberación controlada.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001199484 | 2001-06-29 | ||
| JP2001340993 | 2001-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034641A1 true AR034641A1 (es) | 2004-03-03 |
Family
ID=26617910
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102406A AR034641A1 (es) | 2001-06-29 | 2002-06-26 | Composicion de liberacion controlada y metodo para producirla |
| ARP140104096A AR098261A2 (es) | 2001-06-29 | 2014-11-03 | Composición de liberación controlada y método para producirla |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104096A AR098261A2 (es) | 2001-06-29 | 2014-11-03 | Composición de liberación controlada y método para producirla |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US7429559B2 (es) |
| EP (3) | EP1949936B1 (es) |
| JP (5) | JP2003206240A (es) |
| KR (2) | KR100961413B1 (es) |
| CN (3) | CN100577206C (es) |
| AR (2) | AR034641A1 (es) |
| AT (3) | ATE509668T1 (es) |
| AU (2) | AU2002311631B2 (es) |
| BR (1) | BRPI0210561B8 (es) |
| CA (1) | CA2455392C (es) |
| CO (1) | CO5540367A2 (es) |
| CR (1) | CR11283A (es) |
| CY (2) | CY1105071T1 (es) |
| CZ (1) | CZ306327B6 (es) |
| DE (2) | DE60211464T3 (es) |
| DK (2) | DK1330293T4 (es) |
| ES (2) | ES2366677T3 (es) |
| HU (1) | HU230351B1 (es) |
| IL (3) | IL159059A0 (es) |
| MX (1) | MXPA03011456A (es) |
| MY (1) | MY142066A (es) |
| NO (1) | NO331883B1 (es) |
| NZ (2) | NZ541884A (es) |
| PE (1) | PE20030066A1 (es) |
| PL (1) | PL204903B1 (es) |
| PT (2) | PT1330293E (es) |
| RU (1) | RU2301661C2 (es) |
| SG (1) | SG180015A1 (es) |
| SI (1) | SI1949936T1 (es) |
| SK (1) | SK287577B6 (es) |
| TW (2) | TWI332407B (es) |
| WO (1) | WO2003002092A2 (es) |
| ZA (1) | ZA200309152B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2316273A1 (en) | 1998-01-16 | 1999-07-22 | Takeda Chemical Industries, Ltd. | Sustained-release composition, method of its production and use thereof |
| TWI225416B (en) * | 2001-06-29 | 2004-12-21 | Takeda Chemical Industries Ltd | Sustained-release composition and process for producing the same |
| TWI332407B (en) * | 2001-06-29 | 2010-11-01 | Takeda Chemical Industries Ltd | Controlled release composition and method of producting the same |
| PT1532985T (pt) * | 2002-06-25 | 2017-01-20 | Takeda Pharmaceuticals Co | Processo de produção de uma composição de libertação sustentada |
| US20070207211A1 (en) * | 2003-04-10 | 2007-09-06 | Pr Pharmaceuticals, Inc. | Emulsion-based microparticles and methods for the production thereof |
| PT1615959E (pt) | 2003-04-10 | 2013-08-29 | Evonik Corp | Um método para a produção de micropartículas à base de emulsão |
| WO2005009356A2 (en) * | 2003-07-15 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Method for the preparation of controlled release formulations |
| AU2004259209A1 (en) * | 2003-07-23 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
| TW200529890A (en) * | 2004-02-10 | 2005-09-16 | Takeda Pharmaceutical | Sustained-release preparations |
| TW200613012A (en) * | 2004-07-02 | 2006-05-01 | Takeda Pharmaceuticals Co | Sustained-release composition, process for producing the same and use of the same |
| US20060251581A1 (en) * | 2005-05-09 | 2006-11-09 | Mcintyre Jon T | Method for treatment of uterine fibroid tumors |
| US20070149457A1 (en) * | 2005-12-13 | 2007-06-28 | Byron Rubin | Stable solid forms of enterostatin |
| AU2007207618B2 (en) | 2006-01-18 | 2011-03-24 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical compositions with enhanced stability |
| US7858663B1 (en) * | 2007-10-31 | 2010-12-28 | Pisgah Laboratories, Inc. | Physical and chemical properties of thyroid hormone organic acid addition salts |
| JP4564098B2 (ja) | 2006-12-18 | 2010-10-20 | 武田薬品工業株式会社 | 徐放性組成物およびその製造法 |
| US20110319987A1 (en) * | 2009-05-20 | 2011-12-29 | Arsenal Medical | Medical implant |
| KR101811797B1 (ko) | 2013-04-03 | 2017-12-22 | 동국제약 주식회사 | 도네페질을 포함하는 비경구투여용 약제학적 조성물 |
| US20160303242A1 (en) | 2013-12-09 | 2016-10-20 | Durect Corporation | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same |
| CN103751851A (zh) * | 2014-01-17 | 2014-04-30 | 东华大学 | 一种无机/有机多药物控释复合纳米纤维支架的制备方法 |
| KR101558083B1 (ko) * | 2014-04-07 | 2015-10-07 | 에스케이케미칼주식회사 | 약물함유 고분자미립구 제조방법 |
| EA201692083A1 (ru) | 2014-04-16 | 2017-03-31 | Вейкс-Фарма Гмбх | Фармацевтическая композиция для ветеринарии и ее применение |
| US10787920B2 (en) | 2016-10-12 | 2020-09-29 | General Electric Company | Turbine engine inducer assembly |
| KR102089737B1 (ko) * | 2017-11-01 | 2020-03-16 | 한국화학연구원 | 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법 |
| TW202432109A (zh) | 2022-10-31 | 2024-08-16 | 日商武田藥品工業股份有限公司 | 食慾素２型受體促效劑之給藥 |
| WO2025229493A1 (en) | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
| WO2025229492A1 (en) | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Orexin type 2 receptor agonist microcapsules for sustained release dosing |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3297033A (en) | 1963-10-31 | 1967-01-10 | American Cyanamid Co | Surgical sutures |
| US3565869A (en) | 1968-12-23 | 1971-02-23 | American Cyanamid Co | Extrudable and stretchable polyglycolic acid and process for preparing same |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3755558A (en) | 1971-02-23 | 1973-08-28 | Du Pont | Polylactide drug mixtures for topical application atelet aggregation |
| US3839297A (en) | 1971-11-22 | 1974-10-01 | Ethicon Inc | Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures |
| US3912692A (en) | 1973-05-03 | 1975-10-14 | American Cyanamid Co | Process for polymerizing a substantially pure glycolide composition |
| US3890283A (en) | 1973-06-04 | 1975-06-17 | American Cyanamid Co | Process for post-polymerizing polyglycolic acid |
| US4258063A (en) | 1978-06-23 | 1981-03-24 | Henkel Corporation | Self-emulsifying cosmetic base |
| US4249531A (en) | 1979-07-05 | 1981-02-10 | Alza Corporation | Bioerodible system for delivering drug manufactured from poly(carboxylic acid) |
| US4273920A (en) | 1979-09-12 | 1981-06-16 | Eli Lilly And Company | Polymerization process and product |
| PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4479911A (en) | 1982-01-28 | 1984-10-30 | Sandoz, Inc. | Process for preparation of microspheres and modification of release rate of core material |
| US4605730A (en) | 1982-10-01 | 1986-08-12 | Ethicon, Inc. | Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same |
| US4539981A (en) | 1982-11-08 | 1985-09-10 | Johnson & Johnson Products, Inc. | Absorbable bone fixation device |
| FR2537980B1 (fr) | 1982-12-17 | 1986-12-19 | Sandoz Sa | Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation |
| CH656884A5 (de) † | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| CA1256638A (en) | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
| JPH0678425B2 (ja) | 1984-07-06 | 1994-10-05 | 和光純薬工業株式会社 | 重合体の新規製造法 |
| EP0190833B1 (en) | 1985-02-07 | 1991-03-27 | Takeda Chemical Industries, Ltd. | Method for producing microcapsule |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| EP0452111B1 (en) * | 1990-04-13 | 1998-07-15 | Takeda Chemical Industries, Ltd. | Biodegradable high-molecular polymers, production and use thereof |
| JP3277342B2 (ja) | 1992-09-02 | 2002-04-22 | 武田薬品工業株式会社 | 徐放性マイクロカプセルの製造法 |
| US5353086A (en) * | 1993-05-03 | 1994-10-04 | Eastman Kodak Company | Textured surface with canted channels for an automatic tray processor |
| DE4342092B4 (de) * | 1993-12-09 | 2007-01-11 | Zentaris Gmbh | Langwirkende Injektionssuspension und Verfahren zur Herstellung |
| JP3490171B2 (ja) | 1994-02-21 | 2004-01-26 | 武田薬品工業株式会社 | 生体内分解性ポリマーの末端カルボキシル基におけるエステル |
| US5594091A (en) | 1994-02-21 | 1997-01-14 | Takeda Chemical Industries, Ltd. | Matrix for sustained-release preparation |
| US5763513A (en) | 1994-05-19 | 1998-06-09 | Mitsui Toatsu Chemicals, Inc. | L-lactic acid polymer composition, molded product and film |
| JPH08259460A (ja) * | 1995-01-23 | 1996-10-08 | Takeda Chem Ind Ltd | 徐放性製剤の製造法 |
| JP3902272B2 (ja) * | 1995-09-04 | 2007-04-04 | 武田薬品工業株式会社 | 徐放性製剤の製造法 |
| US5922662A (en) * | 1996-08-07 | 1999-07-13 | Colgate Palmolive Company | High foaming nonionic surfactant based liquid detergent |
| ES2221019T3 (es) * | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
| JPH10273447A (ja) * | 1997-01-29 | 1998-10-13 | Takeda Chem Ind Ltd | 徐放性マイクロスフィア、その製造法および用途 |
| AU5678398A (en) | 1997-01-29 | 1998-08-18 | Takeda Chemical Industries Ltd. | Sustained-release microspheres, their production and use |
| CA2316273A1 (en) * | 1998-01-16 | 1999-07-22 | Takeda Chemical Industries, Ltd. | Sustained-release composition, method of its production and use thereof |
| JPH11269094A (ja) | 1998-01-16 | 1999-10-05 | Takeda Chem Ind Ltd | 徐放性組成物、その製造法および用途 |
| US6114495A (en) | 1998-04-01 | 2000-09-05 | Cargill Incorporated | Lactic acid residue containing polymer composition and product having improved stability, and method for preparation and use thereof |
| US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| PT1158014E (pt) * | 1998-12-15 | 2005-04-29 | Takeda Pharmaceutical | Processo para a producao de poliesteres biodegradaveis |
| JP2000238051A (ja) † | 1999-02-23 | 2000-09-05 | Kansei Corp | 表皮シートの発泡成形型へのセッティング方法 |
| JP2001081043A (ja) * | 1999-07-15 | 2001-03-27 | Takeda Chem Ind Ltd | 徐放性組成物、その製造法および用途 |
| MXPA02000461A (es) † | 1999-07-15 | 2002-07-30 | Takeda Chemical Industries Ltd | Composiciones de liberacion prolongada, metodos para producir las mismas y uso de estas. |
| JP3837607B2 (ja) † | 2000-05-29 | 2006-10-25 | Ｔｃｍ株式会社 | マスト用溶接位置決め治具 |
| US7019106B2 (en) † | 2000-08-07 | 2006-03-28 | Wako Pure Chemical Industries, Ltd. | Lactic acid polymer and process for producing the same |
| WO2002043766A1 (en) | 2000-11-29 | 2002-06-06 | Takeda Chemical Industries, Ltd. | Medicinal compositions and process for producing the same |
| AU2002221139A1 (en) | 2000-12-15 | 2002-06-24 | Takeda Chemical Industries Ltd. | Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof |
| TWI332407B (en) * | 2001-06-29 | 2010-11-01 | Takeda Chemical Industries Ltd | Controlled release composition and method of producting the same |
-
2002
- 2002-06-26 TW TW091114000A patent/TWI332407B/zh not_active IP Right Cessation
- 2002-06-26 AR ARP020102406A patent/AR034641A1/es not_active Application Discontinuation
- 2002-06-26 TW TW094113186A patent/TW200526267A/zh unknown
- 2002-06-27 PE PE2002000578A patent/PE20030066A1/es active IP Right Grant
- 2002-06-28 AU AU2002311631A patent/AU2002311631B2/en not_active Expired
- 2002-06-28 PL PL367518A patent/PL204903B1/pl unknown
- 2002-06-28 DE DE60211464T patent/DE60211464T3/de not_active Expired - Lifetime
- 2002-06-28 SK SK1560-2003A patent/SK287577B6/sk unknown
- 2002-06-28 DE DE60225481T patent/DE60225481T2/de not_active Expired - Lifetime
- 2002-06-28 SI SI200230949T patent/SI1949936T1/sl unknown
- 2002-06-28 EP EP08003261A patent/EP1949936B1/en not_active Expired - Lifetime
- 2002-06-28 KR KR1020097001485A patent/KR100961413B1/ko not_active Expired - Fee Related
- 2002-06-28 US US10/182,731 patent/US7429559B2/en not_active Expired - Fee Related
- 2002-06-28 BR BRPI0210561-6 patent/BRPI0210561B8/pt not_active IP Right Cessation
- 2002-06-28 DK DK02738838.8T patent/DK1330293T4/da active
- 2002-06-28 ES ES08003261T patent/ES2366677T3/es not_active Expired - Lifetime
- 2002-06-28 CN CN200610093268A patent/CN100577206C/zh not_active Expired - Fee Related
- 2002-06-28 WO PCT/JP2002/006527 patent/WO2003002092A2/en not_active Ceased
- 2002-06-28 AT AT08003261T patent/ATE509668T1/de active
- 2002-06-28 DK DK08003261.8T patent/DK1949936T3/da active
- 2002-06-28 MY MYPI20022474A patent/MY142066A/en unknown
- 2002-06-28 CA CA2455392A patent/CA2455392C/en not_active Expired - Fee Related
- 2002-06-28 JP JP2002189247A patent/JP2003206240A/ja active Pending
- 2002-06-28 CN CNB2005100896706A patent/CN100348265C/zh not_active Expired - Fee Related
- 2002-06-28 KR KR1020037017129A patent/KR100916173B1/ko not_active Expired - Lifetime
- 2002-06-28 HU HU0400378A patent/HU230351B1/hu unknown
- 2002-06-28 AT AT04076939T patent/ATE387937T1/de not_active IP Right Cessation
- 2002-06-28 CN CNB028130618A patent/CN1292796C/zh not_active Expired - Lifetime
- 2002-06-28 EP EP02738838A patent/EP1330293B2/en not_active Expired - Lifetime
- 2002-06-28 AT AT02738838T patent/ATE326264T1/de active
- 2002-06-28 MX MXPA03011456A patent/MXPA03011456A/es active IP Right Grant
- 2002-06-28 RU RU2004102507/15A patent/RU2301661C2/ru active
- 2002-06-28 PT PT02738838T patent/PT1330293E/pt unknown
- 2002-06-28 NZ NZ541884A patent/NZ541884A/en not_active IP Right Cessation
- 2002-06-28 ES ES02738838T patent/ES2263788T5/es not_active Expired - Lifetime
- 2002-06-28 SG SG2005085675A patent/SG180015A1/en unknown
- 2002-06-28 PT PT08003261T patent/PT1949936E/pt unknown
- 2002-06-28 CZ CZ2003-3493A patent/CZ306327B6/cs not_active IP Right Cessation
- 2002-06-28 NZ NZ529969A patent/NZ529969A/en not_active IP Right Cessation
- 2002-06-28 IL IL15905902A patent/IL159059A0/xx unknown
- 2002-06-28 EP EP04076939A patent/EP1491236B1/en not_active Expired - Lifetime
-
2003
- 2003-11-25 ZA ZA2003/09152A patent/ZA200309152B/en unknown
- 2003-11-25 IL IL159059A patent/IL159059A/en active IP Right Grant
- 2003-12-19 NO NO20035738A patent/NO331883B1/no not_active IP Right Cessation
- 2003-12-22 CO CO03111729A patent/CO5540367A2/es active IP Right Grant
-
2004
- 2004-04-13 JP JP2004117981A patent/JP2004238400A/ja not_active Withdrawn
-
2006
- 2006-07-07 CY CY20061100943T patent/CY1105071T1/el unknown
- 2006-12-01 AU AU2006246508A patent/AU2006246508B2/en not_active Ceased
-
2007
- 2007-10-18 IL IL186782A patent/IL186782A0/en unknown
-
2008
- 2008-07-29 US US12/181,472 patent/US8067030B2/en not_active Expired - Fee Related
-
2009
- 2009-03-18 JP JP2009065612A patent/JP2009167203A/ja not_active Withdrawn
-
2010
- 2010-02-18 CR CR11283A patent/CR11283A/es unknown
- 2010-04-26 JP JP2010101265A patent/JP4819173B2/ja not_active Expired - Lifetime
- 2010-04-26 JP JP2010101264A patent/JP4819172B2/ja not_active Expired - Lifetime
-
2011
- 2011-03-16 US US13/064,282 patent/US8246987B2/en not_active Expired - Fee Related
- 2011-07-15 CY CY20111100692T patent/CY1111708T1/el unknown
-
2012
- 2012-07-13 US US13/548,463 patent/US8815801B2/en not_active Expired - Lifetime
-
2014
- 2014-11-03 AR ARP140104096A patent/AR098261A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5540367A2 (es) | Composicion de liberacion controlada y metodo para producirla | |
| CY1109272T1 (el) | Συνθεση παρατεταμενης απελευθερωσεως περιλαμβανουσα συμπολυμερες γαλακτικου οξεος-γλυκολικου οξεος και μεθοδος παρασκευης της | |
| CO5570652A2 (es) | Productos en gel para la axila, con componente de bloqueo de agua | |
| JP2021502395A5 (es) | ||
| ATE511834T1 (de) | Stealth lipid-nanokapseln, verfahren zu ihrer herstellung und ihre verwendung als träger von wirkstoff(en) | |
| AR022549A1 (es) | Material de sutura de heridas a base de metilideno malonato. | |
| BR0109150A (pt) | Método para administração de um anestésico local a um indivìduo em necessidade de um efeito anestésico local, emplastro, composição, e, recipiente | |
| EE03292B1 (et) | Prootonpumba inhibiitorit sisaldav paljuosaline ravimpreparaat ja selle valmistamise protsess | |
| RU2017122022A (ru) | Композиция для введения нуклеиновой кислоты в клетки | |
| ATE424848T1 (de) | Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen | |
| CA2481365A1 (en) | Occlusive composition comprising a poly (2-cyanoacrylate) monomer | |
| WO2002034705A3 (en) | C-nitroso compounds and use thereof | |
| MXPA03002548A (es) | Composiciones para la liberacion transdermica de fentanil. | |
| AR009301A1 (es) | Procedimiento para preparar un cemento oseo o un material de sustitucion osea que contiene sustancias activas o el correspondiente deposito implantablede liberacion sostenida de farmacos, y un set para preparar un cemento oseo que promueve la liberacion de la sustancia activa | |
| BR112022025855A2 (pt) | Polímero, método de administração de um ou mais agentes de ácido nucleico terapêuticos, de diagnóstico ou profiláticos, ou combinações dos mesmos in vivo | |
| EP1568729A1 (en) | Polysiloxane having phosphorylcholine group and process for producing the same | |
| TW200833376A (en) | Sustained-release composition and method for producing the same | |
| JP2005501141A5 (es) | ||
| EP1197208A4 (en) | COMPOSITIONS WITH DELAYED RELEASE, METHOD FOR THEIR PRODUCTION AND USE | |
| Sato et al. | Nanogel-crosslinked nanoparticles increase the inhibitory effects of W9 synthetic peptide on bone loss in a murine bone resorption model | |
| BR0016940A (pt) | Composições adesivas para dentadura compreendendo um ativador polimérico | |
| AR016806A1 (es) | Procedimiento para la estabilizacion de acido ascorbico levogiro (laa), composicion de laa estabilizado en un medio que contiene agua, emulsion que incluyea dicho laa estabilizado, producto vitaminico que comprende a dicha composicion, procedimiento para preparar dicha composicion y metodo para el t | |
| WO2025170875A1 (en) | Polysilane methacrylic compounds and methods of making them | |
| JP6654057B2 (ja) | 局所麻酔薬を含有するポリイオンコンプレックスを有効成分とする局所疼痛制御用組成物 | |
| FR2864776B1 (fr) | Composition cosmetique de type emulsion eau-dans-eau a base de tensioactifs et de polymeres cationiques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |